Profound Medical Corp. (PROF) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Profound Medical Corp.'s filing signal turned negative.

Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for tissue ablation. Its flagship product, the TULSA-PRO system, utilizes real-time MRI, robotic transurethral ultrasound, and closed-loop temperature feedback for precise prostate tissue ablation, treating conditions like prostate cancer and benign prostatic hyperplasia (BPH). The company also markets the Sonalleve system, which uses MRI-guided focused ultrasound for conditions such as uterine fibroids and palliative bone pain treatment. Profound operates on a hybrid business model, generating revenue from both capital equipment sales and recurring revenue from disposable devices and services. The company has generated revenues in the United States, EU, and Asia, with a primary focus on the U.S. market.

Revenue is driven by the sale of capital equipment (TULSA-PRO and Sonalleve systems) and recurring revenue from one-time-use devices and services associated with extended warranties.